Targets › PARG
4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Poly(ADP-ribose) glycohydrolase that degrades poly(ADP-ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP-ribose). Mainly acts as an exo-glycohydrolase but can act as an endo-glycohydrolase at low efficiency, releasing poly(ADP-ribose) of different length as well as ADP-ribose monomers. (UniProt, Q86W56)
Open in Phaseline: the race on PARG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| 858 Therapeutics | ETX-19477 PARG inhibitor | PARG | Phase 1 | Advanced or Metastatic Solid Tumors | Dec 2026 |
| Evopoint Biosciences | XNW29016 PARG inhibitor | PARG | Phase 1 | Tumor, Solid | Feb 2027 |
| IDEAYA Biosciences | IDE-161 PARG inhibitor | PARG | Phase 1 | Advanced or Metastatic Solid Tumors | May 2027 |
| FoRx Therapeutics | FORX-428 PARG inhibitor | PARG | Phase 1 | Advanced Solid Tumors | Jun 2027 |
Advanced or Metastatic Solid Tumors (2) Advanced Solid Tumors (1) Tumor, Solid (1)
small molecule (3), mixed (1)
FoRx Therapeutics (1) Evopoint Biosciences (1) 858 Therapeutics (1) IDEAYA Biosciences (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.